Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors

Conditions:   HER2+ Advanced Breast Cancer;   Other Solid Tumors Interventions:   Drug: ADCC-R-Epo-R T-cells + Trastuzumab;   Drug: Erythropoietin beta;   Drug: Fludarabine and Cyclophosphosphamide Sponsor:   National University Hospital, Singapore Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials